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Abstract
With knowledge of the molecular behaviour of the cystic ﬁbrosis transmembrane conductance regulator (CFTR), its physiological role
and dysfunction in cystic ﬁbrosis (CF), therapeutic strategies are now being developed that target the root cause of CF rather than disease
symptoms. Here, we review progress towards the development of rational new therapies for CF. We highlight the discovery of small
molecules that rescue the cell surface expression and defective channel gating of CF mutants, termed CFTR correctors and CFTR potentiators,
respectively. We draw attention to alternative approaches to restore epithelial ion transport to CF epithelia, including inhibitors of the epithelial
Na+ channel (ENaC) and activators of the Ca2+-activated Cl− channel TMEM16A. The expertise required to translate small molecules
identiﬁed in the laboratory to drugs for CF patients depends on our ability to coordinate drug development at an international level and our
ability to provide pertinent biological information using suitable disease models.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
The life expectancy of individuals afﬂicted by the common
genetic disease cystic ﬁbrosis (CF) has improved substantially
in recent decades. Over the last 40 years, the median age
of survival of CF patients has increased from around 14
years to approach 40 years in countries with well-funded
healthcare systems [1,2]. This increase in life expectancy has
been achieved by early diagnosis, specialised patient care in
CF centres and improvements in symptomatic therapy [1].
Symptomatic therapy for CF patients includes (i) physiother-
apy, mucolytic drugs, antibiotics and anti-inﬂammatory drugs
to treat lung disease, the major cause of debilitation and
death in CF and (ii) pancreatic enzyme replacement therapy
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and supplementary nutrition to overcome gastrointestinal dys-
function. All these treatments target the consequences of the
underlying genetic defect in CF. By contrast, future therapies
aim to target the root cause of CF, mutations in the cystic
ﬁbrosis transmembrane conductance regulator (CFTR) [3].
CFTR is a multi-functional protein that plays a pivotal
role in transepithelial ﬂuid and electrolyte movements. It
is assembled from ﬁve domains: two membrane-spanning
domains (MSDs), two nucleotide-binding domains (NBDs)
and a unique regulatory domain (RD) [3]. CFTR forms a
tightly regulated anion-selective channel that mediates anion
ﬂow across the apical membrane of epithelia cells [4] and
regulates the activity of other transport proteins in epithelial
cells [5]. Dysfunction of CFTR in CF disrupts ﬂuid and
electrolyte transport across epithelial surfaces throughout the
body and hence, the function of a variety of organs, most
notably the respiratory airways [6,7].
In this review, we discuss the development of drug
therapies to restore function to CF mutants and rehydrate
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epithelial surfaces in CF. These therapeutic strategies target
directly either CFTR or transport proteins in epithelial cells
with which it interacts. The development of these novel
therapeutic strategies is based on a rational understanding
of CFTR structure and function, its physiological role and
dysfunction in CF. For information about gene therapy, the
method of choice to overcome defects in the CFTR gene, we
refer the Reader to Conese et al. [8].
2. Molecular mechanisms of CFTR dysfunction in CF
To date, around 1,500 disease-causing mutations have been
identiﬁed in the CFTR gene (see The Cystic Fibrosis Mu-
tation Database; http://www.genet.sickkids.on.ca/cftr/). Most
mutations are very rare. The exception is the deletion of the
three base pairs which result in the loss of the phenylalanine
residue at position 508 of the CFTR protein sequence (termed
F508del), which accounts for about 70% of CF mutations
worldwide [6]. Studies of the synthesis and function of CFTR
have identiﬁed ﬁve general mechanisms by which mutations
disrupt CFTR function: (i) defective protein production; (ii)
defective protein processing; (iii) defective channel regula-
tion; (iv) defective channel conduction and (v) reduced protein
synthesis [9,10] (Fig. 1).
2.1. Class I mutations: defective protein production
Some CF mutations (e.g. W1282X) are nonsense mutations
that introduce stop signals known as premature termination
codons (PTCs) into the CFTR gene. Individuals bearing class
I mutations fail to produce full-length CFTR protein because
either the mRNA or the protein is unstable and present at
very low levels. Thus, class I mutations cause a loss of
CFTR function because the protein is missing from its correct
cellular location, the apical membrane of epithelia (Fig. 1).
2.2. Class II mutations: defective protein processing
Many CF mutations, including the most common, F508del,
disrupt the processing and intracellular transport of CFTR
[11]. Wild-type CFTR is synthesized in the endoplasmic
reticulum (ER) before being transported to the Golgi for
maturation prior to its delivery to the apical membrane
(Fig. 1). By contrast, F508del is recognised as a mutant
because it is misfolded, retained in the ER and subsequently
degraded by the proteasome (Fig. 1). As a result, the vast
majority of F508del is not transported to the Golgi or the
apical membrane. This accounts for the loss of CFTR function
caused by F508del.
2.3. Class III mutations: defective channel regulation
Opening of the CFTR Cl− channel is tightly-regulated
by (i) RD phosphorylation and (ii) cycles of ATP-binding
and hydrolysis at the NBDs [4,12]. Class III mutations (e.g.
G551D) disrupt channel regulation by affecting the pattern
of channel opening and closing (termed gating) [12]. For
wild-type CFTR, channel openings occur very frequently and
are separated by short periods of channel closure (e.g. [12,
ﬁg. 4A]). By contrast, for G551D channel openings occur
very infrequently and are separated by prolonged periods of
channel closure (e.g. [12, ﬁg. 4B]). Thus, class III mutations
cause a loss of CFTR function because they disrupt channel
regulation (Fig. 1).
2.4. Class IV mutations: defective channel conduction
The membrane-spanning domains (MSDs) contribute to
the formation of the channel pore [4]. Some CF mutants in
the MSDs impair the rate of Cl− ﬂow through open channels,
although they retain their Cl−-selectivity and regulation. For
example, the conductance of an open wild-type CFTR Cl−
channel is ∼8 pS, whereas that of R347P is only 2 pS [13].
An explanation for why mutations at R347 decrease Cl− ﬂow
through CFTR was provided by Tabcharani et al. [14], who
demonstrated that the CF mutant R347H converts CFTR from
a multi-ion pore to a single-ion pore. Thus, class IV mutations
cause a loss of CFTR function because they disrupt anion
ﬂow through the channel pore (Fig. 1).
2.5. Class V mutations: reduced synthesis
Zielenski and Tsui [10] revised the classiﬁcation of CF
mutants proposed by Welsh and Smith [9] to include a further
category of CFTR dysfunction. A number of CF mutants
reduce the synthesis of the CFTR protein, albeit not to the
level of class I and II mutants (Fig. 1). Class V mutants
include promoter mutations that reduce CFTR gene transcrip-
tion and mutations that cause alternative splicing of the CFTR
transcript [10]. Interestingly, Zielenski and Tsui [10] assigned
A455E and P574H, two CF mutations associated with a
milder clinical phenotype (pancreatic sufﬁciency) to Class
V. These mutations disrupt the processing and intracellular
trafﬁcking of CFTR, but not as severely as F508del [15].
Moreover, on reaching the cell surface A455E forms Cl−
channels with open probability (Po), a measure of channel
activity, similar to that of wild-type CFTR, whereas the Po of
P574H exceeds that of wild-type CFTR [15].
The variety of effects of CF mutants on the expression and
function of CFTR argue that no one drug will correct all the
defects caused by CF mutants. Instead, it will be necessary
to tailor speciﬁc therapies to individual CF mutants. Ideally,
these so called mutation-speciﬁc therapies might be used to
treat the ﬁve different classes of CF mutants. However, the
spectrum of defects observed even within individual classes
of CF mutants argues that it might be necessary to personalise
therapy for individual CF patients.
3. Mutation-speciﬁc therapies for CF
Approximately 90% of CF patients carry at least one
copy of F508del, the commonest CF mutation [6]. Thus,
F508del-CFTR is a special focus of CF drug discovery
efforts. As indicated in Section 2.2, F508del is a class II
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Fig. 1. Models showing the synthesis and function of cystic ﬁbrosis transmembrane conductance regulator (CFTR) in an epithelial cell and the mechanism
of dysfunction of cystic ﬁbrosis (CF) mutations. (A) Wild-type CFTR. (B) Class I mutations: defective protein production. (C) Class II mutations: defective
protein processing. (D) Class III mutations: defective channel regulation. (E) Class IV mutations: defective channel conduction. (F) Class V mutations:
reduced synthesis. Abbreviations: N, nucleus; ER, endoplasmic reticulum. The immature, core-glycosylated and mature, fully-glycosylated forms of CFTR are
represented by the single- and multi-branched structures, respectively. For further information, see the text.
mutation that disrupts severely the processing and intracellular
transport of CFTR, leading to the almost complete absence of
mutant protein from the apical membrane of F508del-CFTR
expressing epithelial cells [16,17]. The small amount of
F508del-CFTR that reaches the apical membrane forms Cl−
channels with normal conduction properties, but defective
channel gating [18,19].
Because F508del-CFTR is both a class II and a class III
mutation, pharmacological strategies for this mutation must
address both these types of defects. Small molecules that
overcome the processing defect of F508del-CFTR and trafﬁc
the mutant protein to the apical membrane are termed CFTR
correctors because they rescue the cell surface expression of
the mutant protein. By contrast, small molecules that repair
the gating defect of F508del-CFTR Cl− channels are termed
CFTR potentiators. These agents are so called because they
do not open the F508del-CFTR Cl− channel, but instead they
enhance ATP-dependent channel gating following phosphory-
lation of F508del-CFTR by protein kinase A (PKA). Thus,
a pharmacological therapy for F508del-CFTR requires both
a CFTR corrector and a CFTR potentiator. Although therapy
for CF is mutation-speciﬁc, other CF mutants will likely be
treated using CFTR correctors and CFTR potentiators (i.e.
CFTR correctors: classes II and V; CFTR potentiators: class
III). CFTR potentiators might also be employed to boost
the function of mutant proteins belonging to any class once
they have been delivered to the cell surface. In the following
sections, we discuss the development of therapeutically-active
CFTR correctors and potentiators. Tables 1 and 3 review
preclinical studies of different classes of CFTR correctors
and CFTR potentiators, respectively, whereas Tables 2 and 4
summarise the results of the few clinical trials of these agents
that have been conducted to date. For information about the
development of drug therapy for class I mutations to rescue
CFTR protein production, see [20,21].
3.1. CFTR correctors rescue the processing and trafﬁcking
defects of F508del-CFTR
When cells expressing F508del-CFTR are incubated at
reduced temperature, the mutant protein folds correctly and
trafﬁcs to the cell surface [19]. This observation initiated the
search for CFTR correctors that rescue the apical membrane
expression of F508del-CFTR. One strategy to identify CFTR
correctors is to investigate the effects on F508del-CFTR ex-
pression and function of drugs already approved for use in the
clinic. For example, miglustat, an α-1,2-glucosidase inhibitor
used to treat Type 1 Gaucher’s disease rescued F508del-CFTR
expression and function [22] and attenuated Na+ hyperab-
sorption by cultured CF airway epithelial cells [23]. Based
on these and other results, Actelion Pharmaceuticals Ltd.
(Allschwil, Switzerland) initiated clinical trials of miglustat
for CF patients homozygous for F508del-CFTR (Table 2).
The strategy of choice to identify CFTR correctors is
high-throughput screening (HTS) because there is insufﬁ-
cient information at the current time to design rationally
CFTR correctors. These agents might rescue the processing
and trafﬁcking defects of F508del-CFTR by interacting with
the mutant protein itself or one or more of the multiple
CFTR-interacting proteins that regulate the biosynthesis of
CFTR. HTS exploits a reliable, sensitive, cost effective as-
say to screen libraries of drug-like compounds to identify
lead compounds for medicinal chemistry optimisation. For
example, by screening 150,000 compounds Pedemonte et al.
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Table 1
Studies of CFTR correctors in vitro and in animal models
Compound Ref. Cell system or
animal model *
CFTR isoform Method Results
VERTEX correctors
4-Cyclohexyloxy-2-
{1-[4-(4-methoxy-
benzensulfonyl)-
piperazin-1-yl]-ethyl}-
quinazoline
(VRT-325 or Cor-325)
[25] NIH3T3, HEK-293,
HBEC primary
F508del Voltage-sensitive
ﬂuorescence-based
assay, biochemistry,
electrophysiology
HTS of library containing ∼164,000 compounds
identiﬁed 13 structurally distinct scaffolds with
F508del-CFTR corrector activity. The
quinazolinone VRT-325 was medicinally
optimised from the primary hit VRT-422.
Incubation of primary cultures of CF airway
epithelia with VRT-325 (6.7 μM) for 48 h at
37°C increased the cell surface expression of
F508del-CFTR protein and CFTR-mediated Cl−
secretion.
[29] BHK cells F508del, R258G,
S945L, H949Y
cAMP-stimulated
iodide efﬂux,
biochemistry
VRT-325 (1–10 μM) rescued F508del-CFTR and
other mutants after 48 h incubation of BHK cells
at 37°C. VRT-325 also rescues misprocessed
P-gp mutants and acts as P-gp inhibitor.
VX-809 [26] NIH3T3, HEK-293,
HBEC primary
F508del Biochemistry,
immunocyto-
chemistry,
electrophysiology
Incubation of primary cultures of CF airway
epithelia with VX-809 increased the delivery of
F508del-CFTR protein to the cell surface and
enhanced CFTR-mediated Cl− secretion from 3%
to 15% of values observed in non-CF airway
epithelia.
SERCA inhibitors
Thapsigargin [92] Various cell lines,
F508del mice
F508del Electrophysiology,
MQAE, biochemistry,
NPD
Thapsigargin released ER-retained F508del,
allowing its trafﬁcking to the plasma membrane,
where it has some Cl− channel function.
Treatment of CF mice with thapsigargin modiﬁes
NPD.
Curcumin [93] BHK cell, F508del
mice
F508del NPD, iodide efﬂux,
biochemistry
Oral administration of curcumin to CF mice
corrected the NPD defect. Curcumin also induced
the appearance of functional F508del-CFTR in
BHK cells.
Curcumin [94] CFPAC-1, HeLa cell
lines
F508del Iodide efﬂux,
biochemistry
Curcumin restored functional F508del-CFTR
activity, remodelling of the keratin-18 network
and increased keratin-18 phosphorylation.
Thapsigargin; curcumin;
cyclopiazonic acid
(CPA); 2,5-di(t-butyl)
hydroquinone (DBHQ)
[95] CF15 F508del Iodide efﬂux,
biochemistry
Inhibition of the ER calcium pump maintains a
threshold level of calcium that is correlated to the
recovery of endogenous F508del-CFTR transport
activity. CPA appears the most potent agent.
PLGA nanoparticles
encapsulating
curcumin
[96] F508del mice F508del Nanoparticle
preparation, NPD
Oral administration of PLGA nanoparticles
encapsulating curcumin enhances the efﬁcacy of
curcumin.
Proteasome inhibitors
Epoxomicin, MG-132,
NIP-(Leu)3-vinyl,
AdaLys(bio)Ahx3L3VS
[97] Intestinal tissues F508del-CF
mice
Ussing chamber,
biochemistry,
immunohisto-
chemistry
Incubation of intestinal mucosa with proteasome
inhibitors at 37°C for 2–4 h restored
cAMP-dependent F508del-CFTR activity.
Bortezomib (PS-341;
Velcade)
[98] CF patients, IB3-1 F508del Chloride efﬂux,
biochemistry
Induction of CFTR-mediated Cl− efﬂux,
inhibition of the proteasome and downregulation
of IL-8 levels.
Bortezomib (PS-341;
Velcade)
[99] HEK293 MSR
GripTite cell line
F508del Cellomics high-
content functional
screening
Rescue of F508del-CFTR
Glucosidase inhibitors
NB-DNJ (Miglustat)
and castanospermine
[22,23,
100]
CF15, CFPAC-1,
CFKM4, transfected
COS-7 and CHO
cells, intestinal
tissues
F508del-CF
mice
Electrophysiology,
Ussing chamber,
iodide efﬂux,
biochemistry
Miglustat and castanospermine, two
alpha-glucosidase inhibitors, restored
F508del-CFTR activity by preventing
F508del-CFTR/calnexin interactions in the ER.
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Table 1 (continued)
Compound Ref. Cell system or
animal model *
CFTR isoform Method Results
NB-DNJ (Miglustat) [101] CuFi-1; NuLi-1;
IB3-1
F508del CFTR functional
assay, inﬂammatory
response
Rescue of CFTR function, anti-inﬂammatory
effect of miglustat, reduction of IL-8 and
ICAM-1.
NB-DNJ (Miglustat) [102] CF mice F508del Airway delivery and
NPD measurements
Nasal deposition of low-doses of miglustat
improves both chloride and sodium transport.
Substituted benzo[c]quinolizinium (MPB)
MPB-07, MPB-91 [103] IB3-1, human CF
nasal epithelial cells
F508del Biochemistry, iodide
efﬂux
MPB-07 and MPB-91 restored F508del-CFTR
activity.
MPB-07, MPB-91,
analogues
[104] human CF nasal
epithelial cells, CF15
F508del, G622D Biochemistry, iodide
efﬂux, degradation
assay
MPB compounds protect a proteolytic cleavage
site by directly binding to the NBD1 domain of
F508del-CFTR.
MPB-07 [105] CuFi-1; NuLi-1;
IB3-1
F508del CFTR functional
assay, inﬂammatory
response
Rescue of CFTR function, anti-inﬂammatory
effect of miglustat, reduction of IL-8 and
ICAM-1.
PDE5 inhibitors
Sidenaﬁl (Viagra) [106] human CF nasal
epithelial cells, CF15
F508del,
R1283M
Biochemistry,
immunoﬂuorescence,
iodide efﬂux
Sildenaﬁl restored F508del-CFTR activity by
preventing F508del-CFTR/calnexin interaction in
the ER.
Sildenaﬁl, Vardenaﬁl [107] F508del-mice F508del NPD NPD measurements show activation of Cl− , but
not Na+ transport.
Sidenaﬁl, Zaprinast [108] IB3-1, S9, and
CFBE41o- cells, KO
mice
F508del pH detection,
biochemistry, siRNA,
P. aeruginosa
infection in mice
Reduction of bacterial adhesion to respiratory
epithelial cells, normalization of overexuberant
proinﬂammatory response to bacterial products,
improves CFTR-mediated current.
Sildenaﬁl analogues
(KM11060)
[109] BHK cells F508del HTS assay using
3HA tagged F508del
CFTR, biochemistry
New active compounds were identiﬁed by
screening a library of 43,100 compounds.
Other correctors
Aminoarylthiazoles,
quinazolinylamino-
pyrimidinones,
bisaminomethylbi-
thiazoles (corr4a)
[24,
110]
FRT, BHK,
HBEC-CF primary
F508del YFP cell-based assay
and electrophysiology
HTS of 150,000 compounds yielded several
chemically distinct classes with micromolar
potency that produced greater apical membrane
Cl− current than low-temperature correction of
F508del.
HDAC7 inhibitors
(SAHA)
[111] CFBE41o- cells,
HBEC-CF primary
F508del Biochemistry,
electrophysiology
SAHA restores F508del-CFTR activity; silencing
HDAC7 enhanced F508del stability and
trafﬁcking.
Deoxyspergualine
(DSG)
[112] IB3-1, CFT1, CF15,
C127, LLC-PK1 cell
lines
F508del SPQ assay,
patch-clamp,
biochemistry
Rescue of F508del-CFTR activity.
Human serum
albumin-DSG
[113] CuFi-1; NuLi-1 F508del Iodide and single cell
ﬂuorescence assay
Enhanced rescue of F508del-CFTR activity using
conjugated deoxyspergualine.
This table summarises some studies of small molecule CFTR correctors using cell lines and animal models. Details of the cell system/animal model, CFTR
variant, methods of study and key results are provided. Abbreviations: ER, endoplasmic reticulum; HTS, high-throughput screening; ICAM-1, inter-cellular
adhesion molecule 1; IL-8, interleukin-8; MQAE, 6-methoxy-quinolyl acetoethyl ester; NPD, nasal potential difference; P-gp, P-glycoprotein; PLGA,
poly(lactic-co-glycolic acid); SPQ, 6-methoxy-N-(3-sulfopropyl)quinolinium; YFP, yellow ﬂuorescent protein. For further information, see the text.
*Cellular model used:
Primary cells/tissues: HBE, human bronchial epithelial cells from normal subjects; HBEC-CF primary, human bronchial epithelial cells from CF patients.
Cell-lines (immortalized) expressing endogeneous CFTR: CF15 cells (human nasal airway, F508del/F508del); CFBE41o- (human bronchial origin,
F508del/F508del); CFPAC-1 (human pancreatic duct origin, F508del/F508del); CFT1 (human tracheal origin, F508del/F508del); CuFi-1 (human bronchial
origin, F508del/F508del); NuLi-1 (human bronchial origin, wild-type CFTR); IB3-1 (human bronchial origin, F508del/W1282X); LLC-PK1 (pig kidney
epithelial cell line, wild-type CFTR).
Cell-lines (immortalized) expressing heterologous CFTR: BHK, baby hamster kidney cells; C127, mouse mammary epithelial cells; COS-7, monkey kidney
epithelial cells; FRT, Fischer rat thyroid cells; HeLa, human cervical cancer cell line; HEK 293, human embryonic kidney cells.
[24] identiﬁed several classes of CFTR correctors. In CF
airway epithelial cells homozygous for the F508del muta-
tion, the most promising agents (bisaminomethylbithiazoles)
restored CFTR function to about 8% of that of normal airway
epithelia [24]. Similarly, Vertex Pharmaceuticals Inc. (Cam-
bridge, USA) used HTS to identify lead compounds for the
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Table 2
Clinical trials of CFTR correctors
Compound(s) Ref. Phase of trial Comments
8-cyclopentyl-1,3-dipropylxanthine
(CPX)
Phase 1
(human safety trial),
1997–1999, completed.
This multicentre trial was performed at four institutions and included 37
subjects homozygous for F508del. The study followed a protocol of increasing
single-dose (1, 3, 10, 30, 100, 300, and 1,000 mg) to evaluate the safety,
pharmacokinetics, and efﬁcacy of CPX. Efﬁcacy was determined using NPD
and sweat chloride measurements. Treatment was safe, but there was no
apparent effect of single-dose administration on either NPD or sweat chloride
measurements.
Phenylbutyrate (buphenyl) and
genistein
[114] Pilot trial A standard NPD protocol was used to measure the NPD response to the
combined perfusion of low chloride/isoproterenol/genistein in the 4-PBA-treated
group versus placebo-treated group. Variable NPD responses were reported by
the authors.
Buphenyl [115] Phase 2 20 g t.i.d. Buphenyl produced only a small increase in the NPD response.
Curcuminoids Phase 1
human safety and dose
ﬁnding study
Oral curcuminoids at a dose of 1.5 g t.i.d. and 3.0 g t.i.d. were safe and well
tolerated. Pharmacokinetic data indicated that serum curcumin levels were
below the level of detection following oral dosing. For further information, see
Cystic Fibrosis Foundation web site (www.cff.org).
VX-809 [27] Phase 2a This randomized, double-blind, placebo-controlled trial evaluated the safety and
tolerability of 4 oral doses of VX-809 in adult CF patients homozygous for
F508del-CFTR. Participants received VX-809 (25, 50, 100 or 200 mg) once
daily for 28 days. VX-809 was well tolerated at all doses tested. At high
concentration (100 and 200 mg), VX-809 decreased sweat Cl− concentration.
However, the drug was without effect on lung function (measured by FEV1) and
NPD. For further information, see the Vertex Pharmaceuticals Inc. web site
(http://www.vrtx.com).
Miglustat Phase 2a A proof of concept preliminary phase 2a clinical trial including F508del
homozygous patients given orally 200 mg miglustat is ongoing. For further
information, see the Actelion Pharmaceuticals Ltd. web site
(http://www.actelion.com/en/index.page).
This table summarises clinical studies of small molecule CFTR correctors. Abbreviations: FEV1, forced expiratory volume in one second; NPD, nasal potential
difference; t.i.d., three times daily. For further information, see the text.
development of therapeutically-active CFTR correctors in a
ground-breaking programme funded by the nonproﬁt, donor-
supported organization Cystic Fibrosis Foundation (Bethesda,
USA). In their initial studies [25], Vertex Pharmaceuticals
Inc. identiﬁed the quinazoline compound VRT-325, which
restores CFTR function to CF airway epithelia with simi-
lar efﬁcacy to bisaminomethylbithiazoles [24]. Subsequently,
Vertex Pharmaceuticals Inc. developed VX-809, a potent,
selective and orally bioavailable CFTR corrector that par-
tially restores CFTR expression and function in CF airway
epithelia [26]. Based on the success of preclinical studies,
VX-809 was tested in adult CF patients homozygous for the
F508del-CFTR mutation in a Phase IIa clinical trial to obtain
safety and drug dosing information [27]. Although the drug
was well tolerated by CF patients, it was without effect on
lung function (measured by forced expiratory volume in one
second, FEV1) and nasal potential difference (NPD) [27].
At the present time, the mechanism of action of CFTR
correctors is not completely understood. As indicated above,
these agents might interact directly with CFTR itself or they
might target CFTR-interacting proteins that control CFTR
processing and intracellular transport. Consistent with the
latter idea, Pedemonte et al. [28] demonstrated that rescue
of F508del-CFTR by CFTR correctors is inﬂuenced strongly
by the cell type used for heterologous expression of CFTR.
This result suggests that multiple CFTR correctors targeting
different steps in the biosynthesis of CFTR might be required
to efﬁcaciously rescue the cell surface expression of CFTR.
Clearly, this would be undesirable as a therapeutic strategy.
Much more attractive would be the identiﬁcation of a CFTR
corrector that binds directly to CFTR. The demonstration
that the CFTR potentiator VRT-532 rescues F508del-CFTR
misprocessing [29], suggests that VRT-532 might be such
a compound. If this is the case, this raises the possibility
that it might be feasible to develop small molecules that act
both as CFTR correctors and CFTR potentiators. Such agents
represent the ideal therapy for F508del-CFTR.
3.2. CFTR potentiators restore channel regulation to class III
mutations
To restore channel regulation to class III mutants and
augment the activity of mutant Cl− channels present at the
cell surface, academic groups and pharmaceutical companies
have searched for small molecules that enhance CFTR activ-
ity. Some agents (e.g. bromotetramisole [30]) work indirectly
by modulating the activity of the protein kinases and phos-
phatases that regulate CFTR. By contrast, other agents (e.g.
genistein [31]) interact directly with CFTR to modify channel
gating. This latter group of agents is commonly referred to as
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CFTR potentiators. Prior to the application of HTS to CF drug
discovery, a number of CFTR potentiators were identiﬁed
using in vitro assays (for review, see [32]). However, HTS rev-
olutionised their discovery, expanding greatly the repertoire of
chemical scaffolds with potentiatory activity and identifying
small molecules with greatly increased potency (Table 3).
By HTS and medicinal chemistry optimisation, Vertex
Pharmaceuticals Inc. identiﬁed VX-770, a potent, selective
and orally bioavailable CFTR potentiator [33]. VX-770 (1
μM) restored wild-type levels of channel activity to F508del-
CFTR Cl− channels. Moreover, treatment of CF airway
epithelia (genotype F508del/G551D) with VX-770 (10 μM)
increased airway surface liquid (ASL) volume and ciliary
beat frequency to levels about half those of normal airway
epithelia [33]. Based on these and other results [33], VX-770
became the ﬁrst CFTR potentiator to be tested in the clinic.
The drug was ﬁrst tested in 39 adult CF patients with the
class III mutation G551D, who took the drug orally in a
randomized, double-blind, placebo-controlled trial [34]. VX-
770 was well tolerated by CF patients. But, more importantly,
at high concentration (150 mg), VX-770 decreased sweat Cl−
concentration to approach the normal range (<60 mmol/L)
and lung function (measured by FEV1) improved by 9%
[34]. Following the success of this clinical trial, VX-770
is now being tested in Phase III clinical trials in the USA
and Europe, including studies of children and adults with
the G551D mutation as well as a study of adults carrying
the F508del mutation (www.vrtx.com/current-projects/drug-
candidates/vx-770.html).
Knowledge and understanding of how intracellular ATP
gates the CFTR Cl− channel provides insight into the
mechanism of action of CFTR potentiators. In the ATP-driven
NBD dimerisation model of CFTR channel gating [35,36],
the NBDs form a head-to-tail dimer with two ATP-binding
sites located at the dimer interface [37]. ATP binds tightly
to one ATP-binding site (site 1), whereas ATP is hydrolysed
rapidly at the other ATP-binding site (site 2) [38]. Anion
ﬂow through the CFTR pore is gated by the interaction of
ATP with sites 1 and 2 driving the assembly and disassembly
of the NBD dimer and hence, conformational changes in
the MSDs that lead to opening and closing of the channel
pore [35,36]. Ai et al. [39] ﬁrst proposed that genistein and
other CFTR potentiators might enhance CFTR channel gating
by altering NBD dimerisation. Based on their data [39], the
authors drew three conclusions. First, binding of genistein at
the interface of the NBD dimer might lower the free energy
of the transition state and hence, accelerate channel opening.
Second, genistein might slow the rate of channel closure by
stabilising the NBD dimer. Third, the genistein-binding site
might be located at the dimer interface. Consistent with the
third conclusion, Moran et al. [40] used a molecular model of
the NBD dimer to localise at the dimer interface the binding
site of genistein, apigenin and a series of CFTR potentiators
identiﬁed by HTS. As predicted [31] and veriﬁed [41] by
functional data, this drug-binding site is distinct from the two
ATP-binding sites of CFTR. The success of these studies and
advances in our knowledge of CFTR structure and function
allow us to be optimistic that it will be possible to rationally
design high-afﬁnity CFTR potentiators that restore function to
speciﬁc CF mutants.
4. Non-CFTR approaches to restore epithelial ion
transport in CF
The quantity and quality of epithelial ﬂuids depends on
the balance of absorptive and secretory ion ﬂuxes across
epithelial tissues. These ion ﬂuxes are mediated by a variety
of ion channels and transporters that are tightly controlled
by a complex network of intracellular signaling pathways.
Thus, pharmacological therapies for CF do not need to be
restricted to the CFTR Cl− channel. Here, we consider two
alternative targets in the apical membrane of airway epithelia:
(i) ENaC, which absorbs Na+ to deplete ASL in CF [42]
and (ii) the Ca2+-activated Cl− channel TMEM16A [43], a
favoured target to bypass the loss of Cl− channel function in
CF. Because discussion of other ion channels and transporters
is beyond the scope of this review, we refer the Reader to
Schultz et al. [44] for discussion of how basolateral membrane
K+ channels ﬁne tune CFTR-mediated transepithelial ion
transport and their pharmacological manipulation.
4.1. Pharmacological strategies to downregulate hyperactive
ENaC
In addition to its best-characterised role as a regulated Cl−
channel, CFTR regulates Na+ absorption in airway epithelia
by controlling ENaC activity [45–47]. CFTR negatively
regulates ENaC by decreasing its Po and preventing increases
in [cAMP]i from enhancing ENaC activity [48]. In CF, loss of
CFTR function increases markedly the ENaC-mediated Na+
conductance in human airway [49] and mouse nasal epithelia
[50]. Consistent with these data, overexpression of the β
subunit of ENaC in mouse airway epithelia reproduces many
of the key features of CF lung disease [51,52].
Given the key role of ENaC in ﬂuid and electrolyte
homeostasis in airway epithelia [42], pharmacological in-
hibition of ENaC-mediated Na+ absorption has signiﬁcant
therapeutic potential as a therapy for CF lung disease. One
proposed therapy for the ASL volume depletion in CF is
aerosolized amiloride, a relatively selective open-channel
blocker of ENaC that inhibits Na+ absorption in native hu-
man airway tissues with an IC50 of ≤1 μM [47,49]. The
initial clinical studies of aerosolized amiloride demonstrated
that amiloride inhalation was safe and well tolerated by
CF patients [53–55]. The data also suggested that amiloride
improved mucociliary clearance in CF patients, but that this
effect was short-lived [53–55]. However, subsequent phase II
clinical studies of aerosolized amiloride failed to improve pul-
monary function in CF patients with established lung disease
[56–58]. Interestingly, recent preclinical studies using the
βENaC-overexpressing mouse demonstrated that preventive
intrapulmonary treatment with amiloride (i.e. starting in the
immediate neonatal period prior to the onset of lung dis-
ease) signiﬁcantly reduces airway mucus obstruction, goblet
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Table 3
Studies of CFTR potentiators in vitro and in animal models
Compound Ref. Cell system * CFTR isoform Method Results
8-cyclopentyl-1, 3-di-
propylxanthine (CPX)
and 1,3-diallyl-8-cyclo-
hexylxanthine (DAX)
[116] HEK293, planar lipid
bilayer
WT Electrophysiology CPX and DAX activated CFTR channels
incorporated into planar lipid bilayers,
suggesting that they interact directly with CFTR.
3-isobutyl-1-methyl-
xanthine (IBMX) and
(CPX)
[117] Calu-3 WT and F508del Electrophysiology Phosphodiesterase inhibitors (e.g. CPX and
IBMX) activated wild-type and F508del-CFTR
through cAMP-dependent and -independent
mechanisms.
Genistein [118,
119]
X. laevis oocytes WT Electrophysiology Genistein increased CFTR Cl− currents without
affecting the activity of protein phosphatases or
tyrosine kinases. The authors propose that
genistein interacts directly with CFTR, probably
at a site on the NBDs.
[120] HeLa cells expressing
CFTRs
F508del, G551D Electrophysiology,
NPD assay
Genistein strongly increased G551D-CFTR Cl−
currents. Genistein also enhanced F508del-CFTR
Cl− currents, but only after correction of its
trafﬁcking defect with 4-phenylbutyrate.
Genistein stimulated the NPD of CF patients
bearing the G551D mutation.
[121] NIH3T3 cells F508del, K1250A Electrophysiology Genistein and benzimidazolones shared the same
mechanism of action.
[122] FRT, HNEC-CF
(G551D) primary
WT, G551D Electrophysiology Genistein, but neither CPX nor MPB-07,
rescued transepithelial Cl− transport in G551D
epithelia.
[123] C127 WT Electrophysiology Elevated concentrations of genistein inhibit
CFTR by two mechanisms: (i) potent inhibition
of channel gating (unaffected by voltage and
[Cl−]ext) and (ii) weak open-channel block
(voltage- and [Cl−]ext-dependent).
[124] CHO WT, G551D Electrophysiology,
iodide efﬂux
The CF mutation G551D disrupts the inhibition
of CFTR activity by elevated concentrations of
genistein.
[125] Excised jejuna WT mice Electrophysiology Dietary genistein stimulated anion secretion
across the jejuna of female mice.
Apigenin and apigenin
analogues
[126] Calu-3 WT Electrophysiology Identiﬁcation of the chemical groups responsible
for CFTR potentiation and block by apigenin.
Substituted benzo[c]
quinolizinium (MPB)
[127] CHO, MM39, murine
nasal primary cells, rat
submandibular acini,
human nasal primary
epithelia
WT, CF null
mice
Electrophysiology,
iodide efﬂux
MPB-07 activated wild-type CFTR without
altering the intracellular concentrations of cAMP
and ATP, nor phosphatase activity.
Benzo[c]quinolizinium
and benzo[f]indolo
[2,3-a]quinolizinium
salts
[128] CHO WT, G551D Iodide efﬂux Structure–activity relationships to identify the
structural basis for CFTR activation. The best
compound was 100-fold more potent than the
parental compound MPB-07.
7,8 benzoﬂavones [129] FRT, HBEC primary WT, G551D YFP cell-based
assay and electro-
physiology
Screening of a combinatorial library based on
ﬂavone and benzoquinolizinium structures
yielded a new family of active compounds, 7,8
benzoﬂavones. Some agents also activated
G551D-CFTR.
3-(2-benzyloxyphenyl)
isoxazoles and 3-(2-
benzyloxyphenyl)iso-
xazolines
[130] FRT WT YFP cell-based
assay
New active compounds identiﬁed by screening a
small library of isoxazole and isoxazoline
heterocycles.
7,8 benzoﬂavones [131] HBEC primary, FRT WT Electrophysiology The apparent afﬁnity of compounds depends on
the phosphorylation status of CFTR.
Competition between compounds suggests a
common binding site.
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Table 3 (continued)
Compound Ref. Cell system * CFTR isoform Method Results
Benzoﬂavones
analogues
[132] FRT WT, G551D YFP cell-based assay Analysis of a panel of benzoﬂavones
analogues to analyse structure–activity
relationships and to model a pharmacophore.
CFTRact-01 to
CFTRact-17
[133] FRT, HBEC-CF
(F508del) primary
WT, G551D,
temperature-
corrected F508del
YFP cell-based assay
and electrophysiology
HTS of a 60,000 compound library yielded
14 active compounds from different chemical
families. The most potent compounds had
tetrahydrocarbazol, hydroxycoumarin, and
thiazolidine core structures.
Phloxine B [134] X. laevis oocytes WT Electrophysiology Phloxine B has bell-shaped concentration-
dependent effects on CFTR Cl− currents.
Speculated that phloxine B directly interacts
with CFTR from inside of cell.
[135] C127 WT, temperature-
corrected F508del
Electrophysiology Phloxine B (1 μM) increased the open
probability of wild-type and F508del-CFTR
by slowing the rate of channel closure. At
higher concentrations (40 μM) the drug
blocked the intracellular vestibule of the
CFTR pore.
[136] COS-7 G551D, G1349D,
G551D/G1349D
Electrophysiology,
iodide efﬂux
Study explores the contribution of G551 and
G1349 to CFTR modulation (potentiation and
inhibition) by phloxine B.
[137] C127, FRT WT, G551D,
G1349D
Electrophysiology Phloxine B has distinct effects on G551D and
G1349D-CFTR, suggesting that drug therapy
for CF is mutation-speciﬁc.
dF508act-01 to
dF508act-06
[138] FRT, HBEC-CF
(F508del) primary
Temperature-
corrected F508del
YFP cell-based assay
and electrophysiology
HTS of a library containing 100,000
compounds yielded 32 hits with
submicromolar activating potency; most active
compounds had tetrahydrobenzothiophene,
benzofuran, anthraquinone,
tetrahydrobenzothiophenes, pyramidinetrione
or dihydropyridine core structures.
Capsaicin [39] NIH3T3, CHO WT Electrophysiology Capsaicin is a partial agonist, which
potentiates CFTR, but not as effectively as
genistein.
Curcumin [139] HeLa, COS-7 WT, temperature-
corrected F508del
Electrophysiology Curcumin increased CFTR channel activity by
increasing the frequency and duration of
channel openings.
Phenylglycine and
sulfonamide
[140] FRT, HBEC-CF
(F508del)
Temperature-
corrected F508del
YFP cell-based assay,
electrophysiology
HTS of a library containing 50,000 diverse
small molecules yielded two novel classes of
potentiators that were active with nanomolar
potency on F508del- and G551D-CFTR.
[141] COS-7, HEK293, FRT G551D, G1349D,
E193K, G970R
YFP cell-based assay,
electrophysiology
Study demonstrates that potentiators are active
on mutations residing in different CFTR
domains and that potencies are mutation-
speciﬁc.
5-nitro-2-(3-phenyl
propylamino)benzoate
(NPPB) analogues
[142] BHK, HEK293,
CFBE41o- transfected
WT, F508del,
R-S660A-CFTR
Electrophysiology NPPB analogues stimulate WT and
F508del-CFTR channel activity at
submicromolar concentrations without
blocking the channel pore.
Dihydropyridines
(DHP)
[143] FRT, HBEC-CF
(F508del)
G551D,
temperature-
corrected F508del
YFP cell-based assay,
electrophysiology
Screening of an approved drugs library
identiﬁed some antihypertensive
1,4-dihydropyridines as submicromolar
potentiators of F508del-CFTR and, with less
potency, of G551D CFTR.
[144] FRT G551D, G1349D,
temperature-
corrected F508del
YFP cell-based assay,
electrophysiology
Structure–activity relationships for CFTR
potentiation and Ca2+-channel inhibition
leading to identiﬁcation of compounds that
more potently potentiate CFTR than block
Ca2+-channels.
S138 F. Becq et al. / Journal of Cystic Fibrosis Volume 10 Suppl 2 (2011) S129–S145
Table 3 (continued)
Compound Ref. Cell system * CFTR isoform Method Results
4-Chlorobenzo[F]
isoquinoline (CBIQ)
[145] X. laevis oocytes, FRT WT, F508del YFP cell-based assay,
electrophysiology
CBIQ activates apical membrane CFTR Cl−
channels (wild-type and F508del) and
KCNN4, a calcium-dependent basolateral
membrane K+ channel. This combination of
activities might increase the transepithelial
anion secretion better than CFTR potentiation
alone.
Vertex compounds
4-Methyl-2-(5-phenyl-
1H-pyrazol-3-yl)-
phenol (VRT-532)
[25] NIH3T3, HEK-293,
HBEC primary
F508del Voltage-sensitive
ﬂuorescence based
assay,
electrophysiology
HTS of a library containing 122,000
compounds yielded 10 structurally different
scaffolds that activate F508del-CFTR in both
recombinant cells and HBECs. The pyrazole
VRT-532 was among the most potent with low
micromolar potency. It rescues the gating
defect of F508del-CFTR by prolonging the
duration of channel openings.
[146] BHK F508del Iodide efﬂux; ATPase
activity, limited
proteolysis
Binding of this compound to F508del CFTR
decreases ATP turnover leading to an increase
in channel open time.
N-(2,4-di-tert-butyl-
5-hydroxyphenyl)-
4-oxo-1,4-dihydro-
quinoline-3-
carboxamide
(VX-770)
[33] FRT, NIH3T3, HBEC
primary
WT, G551D and
F508del
Electrophysiology,
ASL height and
ciliary beat frequency
VX-770 increases the open probability of
G551D-CFTR Cl− channels and hence,
stimulates Cl− secretion, apical surface
hydration and ciliary beat frequency of human
bronchial epithelia expressing G551D-CFTR.
VX-770 has received orphan designation by
FDA.
Pyrrolo[2,3-b]
pyrazines derivatives
(RP)
[147] CHO, Calu-3, mice
colon
WT, G551D,
temperature-
corrected F508del
Iodide efﬂux,
electrophysiology
The synthesis and screening of a small library
of 6 RP derivatives identiﬁed RP107 as a
submicromolar activator of wild-type and
mutant CFTR.
Sulfamoyl-4-
oxoquinoline-3-
carboxamides
[148] FRT Temperature-
corrected F508del
YFP cell-based assay Screening of a small collection of
sulfamoyl-4-oxoquinoline-3-carboxamides
identiﬁed various compounds with
submicromolar potency as potentiators of
F508del-CFTR.
GPact11a [149] CF mice, cell lines and
primary human airway
epithelial cells
WT, F508del Electrophysiology,
salivary secretion
This non-toxic, water-soluble methylglyoxal
alpha-aminoazaheterocycle adduct activates
CFTR (wild-type and F508del), stimulates
colonic chloride secretion and salivary
secretion in vivo.
This table summarises some studies of small molecule CFTR potentiators using cell lines and animal models. Details of the cell system/animal model, CFTR
variant, methods of study and key results are provided. Abbreviations: ASL, airway surface liquid; HTS, high-throughput screening; NPD, nasal potential
difference; YFP, yellow ﬂuorescent protein. For further information, see the text.
*Cellular model used:
Primary cells/tissues: HBE, human bronchial epithelial cells from normal subjects; HBEC-CF primary, human bronchial epithelial cells from CF patients.
Cell-lines (immortalized) expressing endogeneous CFTR: Calu-3 (human submucosal gland; wild-type CFTR); CFBE41o- (human bronchial origin,
F508del/F508del); MM39 (human tracheal gland; wild-type).
Cell-lines (immortalized) expressing heterologous CFTR: BHK, baby hamster kidney cells; C127, mouse mammary epithelial cells; CHO, Chinese hamster
ovary cells; COS-7, monkey kidney epithelial cells; FRT, Fischer rat thyroid cells; HeLa, human cervical cancer cell line; HEK 293, human embryonic kidney
cells; NIH3T3, mouse ﬁbroblasts.
cell metaplasia, mucus hypersecretion, airway inﬂammation
and pulmonary mortality in this model of CF lung disease
[42,51,52,59]. These results demonstrate convincingly that
amiloride can be delivered to the lung in therapeutically-
active quantities prior to the onset of lung disease. They
also suggest that airway mucus obstruction and/or airway
remodeling might contribute to the lack of therapeutic beneﬁt
of aerosolized amiloride in older βENaC-overexpressing mice
and CF patients with established lung disease [52]. Amiloride
is readily available, inexpensive and has been employed clin-
ically as a diuretic for more than a decade. These properties,
together with the widespread implementation of CF newborn
screening, which permits the initiation of therapy in pre-
symptomatic CF infants, might facilitate the translation of
preventive amiloride therapy for CF lung disease from mice
to the clinic [42,59].
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Table 4
Clinical trials of CFTR potentiators
Compound(s) Ref. Phase of trial Comments
8-cyclopentyl-1,3-dipropylxanthine
(CPX)
[150] Phase 1
(human safety trial),
1997–1999, completed.
This multicentre trial was performed at four institutions and included 37
subjects homozygous for F508del. The study followed a protocol of increasing
single-dose (1, 3, 10, 30, 100, 300, and 1,000 mg) to evaluate the safety,
pharmacokinetics, and efﬁcacy of CPX. Efﬁcacy was determined using NPD and
sweat chloride measurements. CPX treatment was safe, but there was no effect
of single-dose administration on either NPD or sweat chloride concentration.
VX-770 [34] Phase 1 and 2 completed
Phase 3
This randomized, double-blind, placebo-controlled trial evaluated the safety and
tolerability of VX-770 in adult CF patients with at least one copy of the G551D
mutation. Patients received oral VX-770 every 12 h (25, 75 or 150 mg) for 14
days or oral VX-770 every 12 h (150 or 250 mg) for 28 days. VX-770 was well
tolerated at all doses tested; no subjects withdrew from the study and few severe
adverse events occurred. At high concentration (150 mg), VX-770 decreased the
sweat Cl− concentration to approach the normal range, stimulated NPD and
increased FEV1 by 9%. Thus, VX-770 improved CFTR and lung function in
adult CF patients with the G551D mutation.
This table summarises clinical studies of small molecule CFTR potentiators. Abbreviations: FEV1, forced expiratory volume in one second; NPD, nasal
potential difference. For further information, see the text.
The poor performance of aerosolized amiloride in CF pa-
tients with established lung disease was originally attributed to
its low potency and rapid absorption from the mucosal surface
[60]. To develop an ENaC blocker with higher efﬁciency, se-
lectivity and longer duration of action than amiloride, a series
of novel 2-substituted acylguanidine analogues of amiloride
were synthesized and tested. When compared with amiloride,
Parion 552-02 was 60- to 100-fold more potent, 2- to 5-fold
less reversible and signiﬁcantly slower at crossing the airway
epithelium [61]. Using tracheal potential difference (TPD) as
an assay of ENaC function, Coote et al. [62] demonstrated
that the rank order of ENaC inhibition in vivo was Parion
552-02  benzamil = amiloride  5-(N-ethyl-N-isopropyl)
amiloride. These data suggest that Parion 552-02 is a valuable
lead compound for the development of a novel therapy for CF
lung disease.
Donaldson et al. [63] evaluated the combination therapy of
amiloride and hypertonic saline to enhance the clearance of
mucus from the airways of CF patients by hypertonic saline.
Unexpectedly, when amiloride was inhaled prior to hypertonic
saline, hypertonic saline was less effective than hypertonic
saline alone [63]. An explanation for this paradoxical effect of
amiloride is the inhibition of aquaporins, which are involved
in osmotically-driven water transport to the airway surface
[63]. Because, Parion 552-02 does not inhibit aquaporins, the
combination therapy of hypertonic saline and Parion 552-02
had a synergistic effect on ASL expansion in canine and
CF bronchial epithelia [61]. Thus, the efﬁcacy of aerosolized
Parion 552-02 as a therapy for CF lung disease either alone
or in combination with hypertonic saline warrants further
investigation.
In airway epithelia, ENaC activity is tightly regulated
by proteases and anti-proteases present in ASL [64]. In the
current model of ENaC regulation by channel activating
proteases (CAPs), ENaC is inserted into the apical membrane
of airway epithelial cells in an inactive state where it
is either directly or indirectly activated by CAPs [65–
67]. Interestingly, the Kunitz-type macromolecular serine
protease inhibitors aprotinin and placental bikunin attenuate
ENaC activity in human bronchial epithelial cells derived
from both normal and CF airways, whereas α1-antitrypsin
and soybean trypsin inhibitor (SBTI) are without effect
[65,66]. Of note, both aprotinin and placental bikunin potently
attenuated TPD to a similar degree as that observed with
directly acting ENaC blockers [62]. To conﬁrm whether
aprotinin and placental bikunin were attenuating the ENaC-
mediated component of TPD, the effects of Parion 552-
02 and placental bikunin either alone or in combination
were studied. Because both directly acting (Parion 552-
02) and indirectly acting (placental bikunin) ENaC blockers
attenuated TPD to the same extent and because the effects
of the combination of Parion 552-02 and placental bikunin
did not exceed those of either agent alone, the data argue
that Parion 552-02 and placental bikunin exert their effects
on a common target, ENaC. In search of low-molecular-
weight inhibitors of airway CAPs, Coote and colleagues
[67] tested camostat, a trypsin-like protease inhibitor. In
both in vitro and in vivo models of ENaC function in airway
epithelia, camostat potently inhibited ENaC-mediated currents
for prolonged periods [67]. Moreover, aerosolised camostat
enhanced mucociliary clearance in conscious sheep for at
least 5 h [67]. Taken together, these studies suggest that anti-
proteases might have therapeutic potential for the treatment of
CF lung disease.
4.2. Downregulation of hyperactive ENaC using RNA
interference
RNA interference is a powerful molecular process used by
cells to modulate gene expression. The effect is mediated by
small sequences of approximately 20 to 22 bases that com-
plement a target mRNA leading to its degradation [68]. Caci
and colleagues [69] used short interfering RNA (siRNA) to
investigate the feasibility of down-regulating ENaC function
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in human bronchial epithelial cells. Transfection of siRNA
targetting each of the three ENaC subunits caused long-term
down-regulation of ENaC at the mRNA and protein levels,
leading to signiﬁcant inhibition of ﬂuid absorption [69]. Inter-
estingly, Folkesson and colleagues demonstrated that siRNA
technology can be used in vivo to explore the role of ENaC
in epithelial ion transport in the airways [70,71]. By contrast,
Griesenbach et al. [72] found that the uptake of small nucleic
acid molecules complexed to the cationic lipid Genzyme lipid
67 (GL67) in mouse airway epithelial cells was inefﬁcient in
vivo with no change in ENaC expression or function being
detected [72]. Therefore, gene transfer vectors, which (i)
target airway epithelial cells from the apical surface, (ii) can
be used repeatedly without eliciting either inﬂammatory or
immune responses and (iii) integrate into the host genome to
achieve persistent down-regulation of ENaC expression are
warranted (for further information, see Conese et al. [8]).
4.3. Use of Ca2+-activated Cl− channels to bypass the loss of
CFTR function in CF
Besides CFTR, CF airway epithelia possess other types of
Cl− channels, most notably the Ca2+-activated Cl− channel
(CaCC) [73]. Thus, a further approach to restore ASL to
CF airway epithelia is to bypass the loss of CFTR function
by activating these alternative Cl− channels. Early studies
demonstrated that CaCCs are present in normal and CF
airway epithelia [74,75]. They also revealed that CaCCs are
activated by extracellular nucleotides (ATP and UTP) binding
to purinergic P2Y2 receptors, which trigger an increase
in the intracellular Ca2+ concentration [74,75]. Because
activation of P2Y2 receptors also inhibits ENaC-mediated
Na+ absorption in CF airway epithelia [76], P2Y2 receptor
agonists are attractive candidates as therapeutics for CF lung
disease. However, the action of extracellular nucleotides at
P2Y2 receptors is short-lived leading to transient activation
of CaCCs and ﬂeeting increases in ASL [77]. To achieve
sustained activation of CaCCs, long-acting, metabolically-
stable P2Y2 agonists have been developed. For example,
denufosol tetrasodium (INS37217) improved lung function
in CF patients with mild lung disease (FEV1 ≥ 75%) when
tested in Phase II clinical trials of up to 28 days duration
[78]. However, in Phase III clinical trials at the Week 48
endpoint, there was no signiﬁcant difference in lung function
(as measured by FEV1) between denufosol and the placebo
(http://www.inspirepharm.com/r_and_d/denufosol.php).
To target directly CaCCs in CF airway epithelia with
small molecule activators, the molecular identity of CaCC is
required. Although for many years the molecular identity of
CaCC remained elusive, in 2008 three groups demonstrated
that TMEM16A functions as a CaCC in several tissues includ-
ing airway epithelia [79–81]. The discovery of TMEM16A
raises the possibility of using HTS to identify small molecule
modulators of CaCCs. For example, by screening >100,000
compounds, Namkung et al. [82] identiﬁed four novel classes
of TMEM16A inhibitors that are without effect on intracel-
lular Ca2+ signalling. These data presage the identiﬁcation
of high-afﬁnity small molecule TMEM16A activators. Such
agents will likely be valuable lead compounds for the devel-
opment of CFTR bypass therapy.
5. Translation to the clinc
The application of HTS to CFTR drug discovery has
led to the discovery of a wealth of small molecules that
rescue the expression and function of CF mutants [83]. The
pressing challenge for the CF community is to transform
discoveries in the laboratory into effective therapies for CF
patients. The pioneering efforts of Vertex Pharmaceuticals
Inc. demonstrate convincingly the therapeutic potential of
small molecules that target directly CFTR. However, they also
highlight deﬁciencies in our knowledge and understanding of
the pathogenesis of CF and the limitations of current research
tools.
The amount of function that must be restored to individ-
ual CF mutants to achieve therapeutic beneﬁt is currently
unknown. Some attempts have been made to address this
fundamental question by analysing published data on the re-
lationship between the genotype of CF patients, their clinical
phenotype and the effects of CF mutants on the CFTR Cl−
channel. For example, Van Goor et al. [25] speculated that
restoration of 5–30% of wild-type function to CF patients
bearing the F508del mutation would be of therapeutic beneﬁt.
Using biochemical and functional data and the relationship
ICFTR = N × i × Po, (ICFTR, CFTR-mediated apical mem-
brane Cl− current; N , the number of CFTR Cl− channels
in the apical membrane; i , the amount of current that ﬂows
through an open CFTR Cl− channel and Po, a measure of its
activity), it is possible to predict how much function different
therapeutic strategies restore to CF mutants in vitro [84]. By
contrast, it is not possible to quantify CFTR function in vivo
using currently available research tools (e.g. the NPD assay),
while measures of lung function (e.g. FEV1) lack sensitivity
during the early stages of lung disease. These considerations
argue that improvements in disease bio-markers and therapeu-
tic end-points will likely be required to determine how much
CFTR function is required for therapeutic beneﬁt.
A further obstacle for CF drug development is the use of
animal models to demonstrate therapeutic proof of principle.
βENaC-overexpressing mice are a valuable model for the
preclinical evaluation of therapeutic interventions that target
increased airway Na+ absorption, ASL depletion and airway
mucus obstruction [42,52]. By contrast, the failure of mouse
models of CF to recapitulate the clinical features of CF [85]
limits their use in the preclinical evaluation of experimental
therapeutics. Furthermore, the lack of effect of CFTR po-
tentiators on murine CFTR [86,87] argues that these agents
should not be tested in CF mice. To overcome these difﬁcul-
ties Vertex Pharmaceuticals Inc. employed well-differentiated
primary cultures of human airway epithelia grown at an
air–liquid interface for therapeutic proof of principle studies
[33]. Using these cultures, Van Goor et al. [33] demonstrated
that the CFTR potentiator VX-770 restores CFTR-mediated
transepithelial ion transport, rehydrates airway surfaces and
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increases ciliary beat frequency. The success of these studies
argues that primary cultures of human airway epithelia will
likely be the model system of choice for future proof of
principle studies of experimental therapeutics. However, the
development of new animal models of CF (e.g. CFTR knock-
out pigs [88]) raises the possibility that these animal models
might be employed to evaluate small molecule therapies that
target the root cause of CF.
Finally, what are the prospects for the rational design
of CFTR correctors and potentiators? In the case of CFTR
potentiators their binding sites on CFTR are beginning to
be revealed [40]. Precise mapping of these binding sites
will require further understanding of the structure of CFTR
and how it is perturbed by CF mutations. In the case of
CFTR correctors, rational design appears a more distant goal
given the complexities of CFTR processing and intracellular
transport. This being the case, new approaches to screening
for CFTR correctors should be considered. One possibility
might be use cell-free assays of CFTR protein folding
to identify small molecules that rescue the F508del-CFTR
folding defect.
Thus, the challenge of tailoring speciﬁc small molecule
therapies to individual CF patients should not be underesti-
mated. The expertise to develop a lead compound identiﬁed
in the laboratory into a marketable drug for CF will depend
equally on our ability to coordinate drug development at an
international level with our ability to provide pertinent biolog-
ical information using suitable disease models. In this regard,
the EuroCareCF project has resulted in a number of welcome
initiatives for CF drug development in Europe. First, in col-
laboration with the European Cystic Fibrosis Society (ECFS),
EuroCareCF developed a European CF Patient Registry
containing demographic data for 29,095 CF patients from 35
countries [89]. Second, EuroCareCF helped the ECFS develop
a European Clinical Trials Network to facilitate cooperation
between clinical trials centres and sponsors in accordance
with the European regulatory directives on clinical trials [90].
Third, participants of the EuroCareCF project co-authored
several reports on CF drug development, including one ad-
dressing the needs and obstacles of small and middle-sized
companies [91]. Taken together, these initiatives will help to
facilitate the development of new therapies for CF patients.
6. Conclusion
Two decades after the identiﬁcation of the defective
gene responsible for CF, therapies based on a molecular
understanding of the disease are beginning to be tested in the
clinic. Early results from these trials are encouraging. They
raise the prospect of personalised medicine, whereby speciﬁc
therapies are designed to target precisely the genetic defects
harboured by individuals afﬂicted by CF.
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